Combination drug therapy for newly diagnosed high-risk follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is testing a combination of three drugs—zanubrutinib, obinutuzumab, and lenalidomide—as a first treatment for people with a certain type of follicular lymphoma that is considered high-risk. The goal is to see if this combination is safe and effective in controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have follicular lymphoma (grade 1, 2, or 3A) that has not yet been treated.
- Your cancer is considered high-risk based on a special scoring system (FLIPI-2).
- You have at least one tumor that can be measured on an imaging test (CT or PET scan).
- You do not have active hepatitis B, hepatitis C, or HIV infection.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (GCVP) for people with follicular lymphoma who have not had treatment before. The goal is to see if this combination is effective and safe.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a combination of two targeted drugs, zanubrutinib and obinutuzumab, for people who have just been diagnosed with follicular lymphoma. The goal is to see if this combination works well and is safe.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) for people newly diagnosed with follicular lymphoma. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.